Security record · archived quarter
MLTX
MoonLake Immunotherapeutics · Healthcare · Biotechnology
7Tracked holders
0Δ holders
7.26MShares held
$366.27MReported value
+0New positions
−0Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -13.5% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 59 | +3 | 21.61M | $421.37M | +4 | −1 |
| Q1 2026 | 59 | +5 | 21.19M | $393.03M | +8 | −3 |
| Q4 2025 | 55 | +1 | 18.04M | $237.83M | +3 | −2 |
| Q3 2025 | 15 | +2 | 5.30M | $38.02M | +3 | −1 |
| Q2 2025 | 10 | -1 | 11.33M | $534.65M | +1 | −2 |
| Q1 2025 | 8 | 0 | 5.66M | $221.05M | +2 | −2 |
| Q4 2024 | 8 | 0 | 7.28M | $394.17M | +1 | −1 |
| Q3 2024 | 7 | 0 | 7.26M | $366.27M | — | — |
| Q2 2024 | 7 | — | 8.40M | $369.30M | — | — |
Who holds it · Q3 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 2.98M | +16.4% | $150.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 2.32M | +2.5% | $117.12M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 2.32M | +2.5% | $117.12M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 4 | Marshall Wace ✦ | 1.15M | +5.1% | $58.20M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | Adage Capital Partners ✦ | 505.00K | -72.3% | $25.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 192.06K | -48.5% | $9.68M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 192.06K | -48.5% | $9.68M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 192.06K | -48.5% | $9.68M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 192.06K | -48.5% | $9.68M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 58.41K | -0.1% | $2.95M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Millennium Management ✦ | 51.27K | -76.4% | $2.58M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 145 holders, 61.96M shares, $1.12B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2024 ·
Methodology ·
Get this via the API